Tofacitinib: The Selected Selective JAK Inhibitor in Pediatric Dermatology
January 2024
in “
International Journal of Dermatology Venereology and Leprosy Sciences
”
TLDR Tofacitinib may be safe and effective for treating certain skin conditions in children.
Tofacitinib, a selective JAK inhibitor, is recognized for treating conditions such as psoriatic arthritis and rheumatoid arthritis and shows promise for pediatric dermatological conditions. A literature review indicates that oral tofacitinib may be a safe and effective treatment for refractory juvenile dermatomyositis, atopic dermatitis, alopecia areata, and various psoriasis types. Topically, it is used for vitiligo vulgaris, alopecia areata, and halo naevus. The article emphasizes the need to weigh the benefits and drawbacks before using tofacitinib in pediatric patients.